Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F. Stein Gold*, Jerry Bagel, Stephen K. Tyring, H. Chih Ho Hong, Lev Pavlovsky, Ronald Vender, Andreas Pinter, Adam Reich, Leonidas Drogaris, Tianshuang Wu, Manish Patel, Ahmed M. Soliman, Huzefa Photowala, Vassilis Stakias, Sven Richter, Kim A. Papp
Research output: Contribution to journal › Article › peer-review
10Scopus
citations
Fingerprint
Dive into the research topics of 'Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)'. Together they form a unique fingerprint.